FOLFIRI® and Bevacizumab in First-Line Treatment for Colorectal Cancer Patients: Safety, Efficacy and Genetic Polymorphisms
BMC Research Notes - United Kingdom
doi 10.1186/1756-0500-7-260
Full Text
Open PDFAbstract
Available in full text
Date
April 23, 2014
Authors
Publisher
Springer Science and Business Media LLC